[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335347-105":59,"doc-detail-335347-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","redefining-chimeric-antigen-receptor-t-cell-car-t-regulation-chinas-responses-to-address-secondary-cancer-risks-of-car-t-therapy","Redefining chimeric antigen receptor T-cell (CAR-T) regulation - China’s responses to address secondary cancer risks of CAR-T therapy","","Chimeric antigen receptor T-cell (CAR-T) therapy became a major breakthrough after FDA approval in 2017, driving rapid global research and adoption. With substantial investment, China has advanced quickly in CAR-T construction, manufacturing processes, and treatment strategies, while high therapy costs often exceed basic insurance coverage. Following an FDA November 2023 warning about secondary cancer risks, China’s NMPA introduced preemptive measures, including emphasis on secondary cancers and lifelong monitoring during product approval. Further regulatory actions are still needed, and the authors call for higher IND approval standards and dynamic, real-world-data–based reporting and feedback to strengthen oversight and support sustainable industry growth.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/redefining-chimeric-antigen-receptor-t-cell-car-t-regulation-chinas-responses-to-address-secondary-cancer-risks-of-car-t-therapy/335347/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/redefining-chimeric-antigen-receptor-t-cell-car-t-regulation-chinas-responses-to-address-secondary-cancer-risks-of-car-t-therapy/335347.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why has CAR-T therapy attracted rapid global attention since 2017?","Question",{"text":113,"@type":114},"After FDA approval in 2017, CAR-T therapy marked a major breakthrough in cancer treatment, leading to a surge of research and applications worldwide.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What regulatory concern was raised by the FDA in November 2023?",{"text":118,"@type":114},"The FDA warned about the risk of secondary cancers in patients undergoing CAR-T therapy, which triggered global attention to patient safety.",{"name":120,"@type":111,"acceptedAnswer":121},"What actions has China’s NMPA taken to address secondary cancer risks?",{"text":122,"@type":114},"China’s NMPA implemented a set of measures before product approval, emphasizing secondary cancer risk and requiring lifelong monitoring as part of the approval process for CAR-T products.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335347,1790767995,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":52,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Tan et al. Journal of Hematology & Oncology (2024) 17:90 [https://doi.org/10.1186/s13045-024-01602-0](https://doi.org/10.1186/s13045-024-01602-0)  \nJournal of Hematology & Oncology  \nCORRESPONDENCE Open Access  \nRedefining chimeric antigen receptor  \nT-cell (CAR-T) regulation: China’s responses to address secondary cancer risks of CAR-T therapy  \nRuirong Tan 1†, Rui Li2†, Meng-Yuan Dai3†, Miao Liu4* and Junning Zhao5*  \nAbstract  \nSince the United States Food and Drug Administration (FDA) approved the first chimeric antigen receptor T-cell (CAR-T) therapy in 2017, it has marked a major breakthrough in cancer treatment, leading to a surge in global research and applications in this field. In recent years, China has made rapid progress, quickly catching up through heavy investment in CAR-T construction, preparation processes, and treatment strategies. China’s CAR-T therapy market is driven by substantial pharmaceutical investment targeting its vast population, yet high therapy costs remain uncovered by basic medical insurance. In November 2023, FDA issued a warning about the risk of secondary cancers in patients undergoing CAR-T therapy, sparking global concern. In fact, the China National Medical Products Administration (NMPA) preemptively implemented a series of measures to address the safety concerns of CAR-T therapy, emphasizing the risk of secondary cancers and advising lifelong monitoring as part of the approval process for CAR-T products. Nevertheless, additional regulatory measures are needed to address emerging risks, particularly the threat of secondary cancers. The authors believe that raising the standards for Investigational New Drug (IND) approval and establishing a dynamic reporting and feedback system based on realworld data will strengthen regulatory oversight and support the sustainable growth of the CAR-T industry in China. Keywords CAR-T therapy, Secondary cancers, Drug regulation  \n†Ruirong Tan, Rui Li and Meng-Yuan Dai contributed equally to this work. Correspondence: Junning Zhao, [zarmy@189.cn](zarmy@189.cn); Miao Liu, [mliu0@bwh.harvard.edu](mliu0@bwh.harvard.edu).  \n*Correspondence:  \nMiao Liu [mliu0@bwh.harvard.edu](mliu0@bwh.harvard.edu)[ ](mliu0@bwh.harvard.edu)Junning Zhao [zarmy@189.cn](zarmy@189.cn)  \n1Translational Chinese Medicine Key Laboratory of Sichuan, Sichuan Institute for Translational Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, Chengdu, China  \n2Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China 3Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China  \n4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA  \n5National Key Laboratory of Drug Regulatory Science, National Medical Products Administration (NMPA), Beijing, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nTan et al. Journal of Hematology & Oncology (2024) 17:90  \nTo the Editor  \nSince the United States Food and Drug Administration (FDA) approv","cbCaijyhaWTBYmzH","https://ap.wps.com/l/cbCaijyhaWTBYmzH","pdf",598440,"English","# Abstract\n## Background and regulatory context\n## China’s responses and current measures\n## Remaining gaps and proposed regulatory improvements","[{\"question\":\"Why has CAR-T therapy attracted rapid global attention since 2017?\",\"answer\":\"After FDA approval in 2017, CAR-T therapy marked a major breakthrough in cancer treatment, leading to a surge of research and applications worldwide.\"},{\"question\":\"What regulatory concern was raised by the FDA in November 2023?\",\"answer\":\"The FDA warned about the risk of secondary cancers in patients undergoing CAR-T therapy, which triggered global attention to patient safety.\"},{\"question\":\"What actions has China’s NMPA taken to address secondary cancer risks?\",\"answer\":\"China’s NMPA implemented a set of measures before product approval, emphasizing secondary cancer risk and requiring lifelong monitoring as part of the approval process for CAR-T products.\"}]","Redefining chimeric antigen receptor T-cell (CAR-T) regulation - China’s responses to address secondary cancer risks of CAR-T therapy | PDF",1790010648]